Tech Transfer Roundup: Boehringer Fits Deal Structure To Partner's Expertise

10 May 2017

• By Joseph Haas, Beth Allan, Deanna Kamienski, and Maureen Riordan

Boehringer Ingelheim's Paola Casarosa explains that when her company partners with academia, it looks for the best way to mine that level of expertise rather than trying to fit the collaboration to a preferred deal model. Plus, our roundup includes three cancer-related deals and one for dry eye disease.

Tech Transfer regular column feature image

Boehringer Ingelheim GMBH considers research pacts with academia a key part of its strategy, and while it leans more toward research collaborations than license- or option-based deals, the company tries to be agnostic about which type of deal structure will fit a specific agreement with academic researchers.

Paola Casarosa, BI's corporate VP for business development and licensing/prescription medicines, told Scrip her team uses a case-by-case approach to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

29 Aug 2025

• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

28 Aug 2025

• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

28 Aug 2025

• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

27 Aug 2025

• By Sushmita Panda

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

28 Aug 2025

• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.